Full title: Improving performance of polygenic risk scores for hypertension across two ancestry groups.

Short Title: Improving PRS for HTN across two ancestry groups.

Marguerite R. Irvin, PhD[1], Vinodh Srinivasasainagendra, MS[2], Nicole D. Armstrong, PhD[1], Amit Patki, MS[2], Ulrich Broeckel, MD[3], Zhe Wang[1], Leslie A. Lange, PhD[5], Nita A Limdi[6], Alicia Huerta-Chagoya [7,8,9,10], Joohyun Kim, PhD[11], Maggie C.Y. Ng, PhD [11], Josep M Mercader, PhD[7,8,9,10,12], Hemant K. Tiwari, PhD[2]

[1]Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
[2]Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
[3]Section of Genomic Pediatrics, Department of Pediatrics, Children's Research Institute, The Medical College of Wisconsin, Milwaukee, WI, USA
[5]Department of Medicine, Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA
[6]Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham.
[7]Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
[8]Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
[9]Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA.
[10]Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
[11]Vanderbilt Genetics Institute, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
[12] Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA

Corresponding author
Marguerite R. Irvin, PhD, M.S.
Department of Epidemiology
University of Alabama at Birmingham
Birmingham, AL 35294
irvinr@uab.edu

1   <u>Abstract</u>
2
Polygenic risk score (PRS) methods are evolving, and the benefit of adding functional

annotations to the variant weights has been especially promising. However, less attention has

been given to how the linkage disequilibrium (LD) reference panel used affects the score

performance. In the current study, we compared two Bayesian approaches, one that

incorporates functional annotations (LDpred-funct) and one that does not (PRS-CS), extending

these applications to the hypertension (HTN) trait across two ancestry groups (European

Americans EA, and African Americans, AA). In PRS-CS we used the standard HapMap 3 LD

(HM3) reference panel, as well as a modified multi-ancestry reference panel (TagIt) with better

coverage of variants from multiple ancestries. Individual-level data in 1,533 EA (58% with HTN)

and 8,603 AA (71% with HTN) participants from the Reasons for Geographic and Racial

Differences in Stroke Study (REGARDS) was used to optimize scores across the two

approaches. PRS performance metrics including R^2 and odds ratios (OR) per standard deviation

(SD) were then used to assess PRS performance in 1,270 EA (55% with HTN) and 1,896 AA

(69% with HTN) participants from the Hypertension Genetic Epidemiology Network Study

(HyperGEN).   Among EAs in HyperGEN we observed an R^2 of 6.0% for LD-Pred-funct and R^2

of 7.3% for PRS-CS-TagIt versus R^2 of 1.4% for PRS-CS-HM3. The magnitude of the OR per

SD for HTN was also higher for PRS-CS-TagIt OR=2.17 (95% CI 1.65-2.85, p=$3.0*10^{-8}$) and LD-

Pred-funct OR=2.14 (95% CI 1.61-2.85, p=$1.46*10^{-7}$) versus PRS-CS-HM3 (OR=1.40; 95% CI

10.8-1.82). Among AAs in HyperGEN, the improvements were more modest, where we

observed R^2 of 1.9% for LD-Pred-funct and R^2 of 2.9% for PRS-CS-TagIt versus 0.7% for PRS-

CS-HM3. We found that both annotations and the updated LD panel improved the scores in

both ancestry groups, but did not make the scores more equitable across the groups.

26
27
28

Author Summary

Genomics can aid in risk prediction and prevention. Polygenic risk score (PRS) development

and application is becoming more popular because there's a lot of genetic data available for

training PRS, and they have the potential to be useful in healthcare. However, PRS are not yet

widely used in clinics, and the methods are still developing. Early PRS methods only used

certain genetic markers, but newer ones use more data and better models to try to predict

disease risk more accurately. Still, these tools often don't work as well for people from

underrepresented populations, which could increase health inequalities. Researchers are trying

to fix this by using more up-to-date data and adding extra information about how genes function.

In our study of HTN, we investigated newer approaches which made PRS more accurate for

both for African American individuals and European American individuals—but they didn't fully

close the performance gap between the groups.

69 <u>Introduction</u>
70
Genome-wide association studies (GWAS) have uncovered a great deal about the

polygenic architecture of common complex disorders. Although GWAS results have been

largely challenging to translate into clinical settings, applications involving polygenic risk scores

(PRS) show promise for clinical utility.(1) Methods for PRS are evolving, and standard pipelines

for derivation and implementation have been proposed but are not yet established.(2) Other

challenges include the varying performance of PRS across populations with diminished

predictive capacity in minority populations.(3) This is most likely due to linkage disequilibrium

(LD) patterns that vary across populations, and the overrepresentation of European Ancestry

individuals (EAs) in genetic databases leveraged to create PRS. Strategies for improving

performance are emerging but may still leave some ancestry groups behind. (4)

Currently, there is no standard method for polygenic prediction. Common approaches

include pruning and thresholding (P+T) which sums the effect size of variants filtered on LD and

evidence of association.(5) Alternatively, Bayesian polygenic prediction methods aim to capture

variants genome-wide and, thus, do not attempt to identify a minimal subset of variants, but

shrink their effects based on their LD.(6-9) These methods use prior distributions paired with

advanced modeling techniques, GWAS summary statistics, and an external LD reference panel

to estimate the posterior mean effect sizes.   For instance, the PRS-CS method uses continuous

shrinkage priors to enable SNP-specific adaptive shrinkage while allowing for diverse underlying

genetic architectures across SNPs.(6) Another widely used method, LDPred, applies a point-

normal prior for the SNP effect sizes after assuming there is an optimized proportion of causal

variants for the trait of interest. (8, 10) Functional annotations can help prioritize more causal

variants and LDPred has been extended to LDpred-funct by adding functional annotation

information to the priors to estimate the mean causal effect sizes.(11)

While many comparisons have been made between PRS development approaches, the

benefit of adding functional annotations to available methods is becoming increasingly evident.

As functional annotations may be more likely to differentiate causal SNPs from non-causal

SNPs in high LD, they may help harmonize translation performance across ancestral groups.

(12) Less attention has been given to the impact the chosen LD reference panel has on the

variant's selection process. Expanding the variants available in the leveraged multi-ancestry

reference panel may improve PRS performance by better capturing linkage disequilibrium

patterns across diverse populations. In the current study, we compared LDpred-funct

performance to PRS-CS, which does not include functional annotations, extending these

applications to hypertension (HTN) across two ancestry groups (European Ancestry, EA and

African Ancestry, AA). In the PRS-CS program, we utilized the standard HapMap 3 (HM3) LD

reference panel, as well as a modified multi-ancestry reference panel (TagIt) with a better

coverage of variants from multi-ancestry populations. (13) Our study assessed these methods

using individual-level data in 1,598 EA and 8,603 AA participants with GWAS from the Reasons

for Geographic and Racial Differences in Stroke Study (REGARDS) and 1,270 EA and 1,896

AA participants with GWAS from the Hypertension Genetic Epidemiology Network Study

(HyperGEN).(14, 15) For each approach, REGARDS served as the optimization cohort and

HyperGEN as the validation cohort.

112
113
114
115   Results
116
Demographic data for the testing and validation cohorts is provided in **Table 1**.

REGARDS participants on average were older than HyperGEN participants. Both cohorts had a

higher percentage of females and larger case versus control counts due to the older

(REGARDS) and hypertensive population (HyperGEN) sampling. The count of variants per

score are presented in **Table 2** with fewer variants included for the PRS-CS method (~800K-2M

variants) and close to three times more variants represented in scores generated by LD-Pred-

funct (≥3.5M variants).

Table 1: Cohort Characteristics

Cohort	Age (±SD)	Sex (% female)	N HTN Case	N HTN Control
Optimization				
REGARDS AAs	63.59 (9.20)	60.98%	6146	2457
REGARDS EAs	68.34 (10.38)	42.30%	896	637
Validation				
HyperGEN AAs	47.01 (12.81)	63.52%	1315	581
HyperGEN EAs	49.83 (13.94)	50.47%	697	573
AA-African American, EA-European American, HTN-Hypertension				

126
127

Table 2: Variants Count by Method and LD Panel

Cohort	Ancestry	PRS Method	LD Panel	Variants Count
REGARDS	EA	PRS-CS	HM3	1,096,331
	AA		HM3	1,198,248
HyperGEN	EA		HM3	886,230
	AA		HM3	1,173,942
REGARDS	EA		TagIt	1,428,183
	AA		TagIt	1,855,205
HyperGEN	EA		TagIt	1,102,428
	AA		TagIt	1,815,423
REGARDS	EA	LDPred-funct	HM3	4,538,902
	AA		HM3	4,003,542
HyperGEN	EA		HM3	3,530,155
	AA		HM3	3,784,296
AA-African American, EA-European American, HTN-Hypertension, LD-linkage disequilibrium, HM3-HapMap 3, TagIt-Tag(ging) It(erative) of SNPs				

128
129
The results represented as OR per SD of the PRS optimized in REGARDS and tested in

HyperGEN are presented in **Table 3**. Based on R^2 the Phi of 1x10^{-04} was tested in PRS-CS in

HyperGEN. Effect sizes and R^2 were higher in EAs compared to AAs in both REGARDS and

HyperGEN across each method. For instance, the OR for LD-Pred-funct in HyperGEN EAs was

2.14 (95% CI: 1.61-2.85) versus 1.37 (95% CI: 1.19-1.58) for AAs. In both ancestry groups,

scores created by adding functional priors (LDPred-funct) and expanding the reference panel

(PRS-CS-TagIt) had improved R^2 compared to PRS-CS-HM3.   We observed R^2 of 6.0% for LD-

Pred-funct and R^2 of 7.3% for PRS-CS-TagIt in EAs from HyperGEN versus R^2 of 1.4% for PRS-

CS-HM3 (**Table 3**). Among AAs in HyperGEN, the improvements were more modest, where we

observed R^2 of 1.9% for LD-Pred-funct and R^2 of 2.9% for PRS-CS-TagIt versus 0.7% for PRS-

CS-HM3. See **Figure 2** for comparisons of R^2 by model by cohort. See **Supplementary Table**

1 for the full results for each model for each cohort.

142
143
144
145

Table 3: HTN Results per 1 standard Deviation of the PRS						
Cohort	PRS Method	Parameter	OR (95% CI)	P	R^2	AUC PRS
REGARDS EAs	PRS-CS-HM3	1×10^{-04}*	1.37 (1.23-1.53)	1.02E-08	2.71E-02	0.58
	PRS-CS-TagIt	1×10^{-04}*	1.73 (1.54-1.94)	4.48E-21	7.79E-02	0.64
	LDPred-funct	-	1.51 (1.35-1.68)	3.74E-13	4.46E-02	0.61
HyperGEN EAs	PRS-CS-HM3	$1\times10^{-04*}$	1.40(1.07-1.82)	1.19E-02	1.37E-02	0.56
	PRS-CS-TagIt	$1\times10^{-04*}$	2.17 (1.65-2.85)	3.00E-08	7.25E-02	0.61
	LDPred-funct	-	2.14 (1.61-2.85)	1.46E-07	6.03E-02	0.60
REGARDS AAs	PRS-CS-HM3	1×10^{-04}*	1.25 (1.19-1.32)	1.39E-16	1.76E-02	0.56
	PRS-CS-TagIt	1×10^{-04}*	1.28 (1.21-1.35)	5.36E-19	2.06E-02	0.57
	LDPred-funct	-	1.32 (1.25-1.39)	5.20E-24	2.66E-02	0.57
HyperGEN AAs	PRS-CS-HM3	1×10^{-04}*	1.20 (1.04-1.39)	1.15E-02	6.70E-03	0.53
	PRS-CS-TagIt	1×10^{-04}*	1.47 (1.27-1.69)	1.14E-07	2.94E-02	0.55
	LDPred-funct	-	1.37 (1.19-1.58)	1.76E-05	1.93E-02	0.52
*Best model Phi REGARDS, AA-African American, EA-European American, HM3-HapMap 3 LD Panel, TagIt-Tag(ging) It(erative) of SNPs LD Panel, AUC-Area Under the Curve						

146
147
148
149

Figure 2. HTN R^2-liability comparison by method per 1 SD of PRS.

PRS threshold results (e.g. top 2% of the PRS distribution versus bottom 98%), are presented in **Supplementary Tables 1a** and **1b** in REGARDS EAs and AAs and **Supplementary Tables 2a** and **2b** for HyperGEN EAs and AAs, respectively. The PRS-CS-TagIt panel and LD-Pred-funct models had stronger associations with HTN at the four tested thresholds than the PRS-CS-HM3 model. For example, being in the top 5% of the PRS distribution for the score generated in LD-Pred-funct was associated with OR=8.10 (95% CI:2.48-26.51) and p=5.4x10^{-04} in HyperGEN EAs. The comparable model for PRS-CS-TagIt (phi 1x10^{-04}), for the 5% threshold had OR=7.98 (95% CI: 2.27-28.00) and p=1.2x10^{-03}. The AUC for the PRS-only model was 0.52 for both approaches (LD-Pred-funct and PRS-CS-TagIt) for the 5% threshold. The 5% threshold PRS-CS-HM3 model for EAs in HyperGEN was not significant (p=1.4x10^{-01}). Generally, across the models in HyperGEN EAs sensitivity was low

(<13.5%) and specificity was high (>0.86). The adjusted PPVs ranged 0.32-0.77 and the

adjusted NPVs ranged 0.43-0.47. For HyperGEN AAs for LD-Pred-funct the 5% threshold

model had an OR of 2.50 (95% CI: 1.32-4.70) with p=4.6*10^{-03}. The comparable model for

PRS-CS-TagIt (phi 1x10^{-04}) for the 5% threshold had OR=3.50 (95% CI: 1.72-7.09) and

p=5.3x10^{-04}. Additionally, the sensitivities and specificities reported were consistently low and

high, respectively for HyperGEN AAs (sensitivity <0.11 and specificity >0.88). ROC curves for

REGARDS and HyperGEN are presented in Supplementary Figure 1.

176
177
178
179
180   Discussion

181
182   PRS is increasingly popular given accessibility of large-scale GWAS summary data

resources as well as the potential for broad clinical applications. Thus far, clinical translation

remains limited, but methods are rapidly evolving. The first PRS approaches such as P+T

subset GWAS SNPs based on different thresholds of significance and LD, while later Bayesian

methods included a wider set of SNPs with more sophisticated modeling to improve the capture

of trait heritability. (5, 16, 17). Current methods can be especially limiting for underrepresented

groups and revised PRS development strategies are needed to ensure that new health

disparities are not created in implementing PRS.(17) Adding functional annotations may help

prioritize variants that are more consistent across ancestry groups.(18) Further, the standard

approaches have also relied on older LD reference panels that may not capture an accurate

representation of LD for diverse groups.(6, 11) In the current study we evaluated both functional

annotations and an updated reference panel for improved performance of PRS for HTN, a

common, heritable chronic disease in both EA and AAs. We found that both annotations and

the updated panel improved the scores in both race groups, but did not make the scores more

equitable across the groups.

197   The accuracy of PRS depends on several factors including the SNP selection and the

truthfulness of their estimated effect sizes. Given evidence suggesting that common causal

variants are likely to be shared across populations, it's been hypothesized that functional

annotations can be used to discriminate probable causal SNPs from other SNPs in high LD with

them for better genomic prediction. (11, 19-23) However, prioritizing these variants is

challenging because numerous common causal variants in LD, often with modest effect sizes,

underly complex traits. (24, 25) In our study the scores created by LDPred-funct had many more

variants (~3X more) than for PRS-CS which could have diluted the effects for more important

SNPs. For multi-ancestry and cross-ancestry prediction, the accuracy is additionally influenced

by how well the LD in the GWAS summary statistics population and the LD panel match the

optimization population. A mismatch can be an important contributor to the loss in PRS

prediction accuracy in cross and multi-ancestry settings. (26) Therefore, in addition to functional

annotations we also considered how updating the reference panel to a more diverse set of

variants/samples could improve PRS for HTN. To date, a popular Bayesian method has used

HM3 variants in 1000G LD data to construct PRS.(6) This was mostly aimed at managing

computational resources while capturing overrepresented European ancestry genetic variation

from large-scale GWAS summary data. However, HM3 variants are known to miss signals

specific to other ancestry groups. We tested whether an expanded reference panel that includes

a more diverse set of 1000G variants may overcome some of those issues by leveraging the

PRISM Consortium TagIt panel in PRS-CS that captures >1 million more SNPs than the PRS-

CS HM3 default panel.(13, 27) Our results show expanding the reference panel and functional

annotations both improved performance to a comparable degree in EAs.   Data on changing out

the LD reference panel in PRS derivation is mixed given expansion.(11-13) One study showed

increasing the sample size of the representative LD reference dataset linearly improved R^2.(12)

In the context of T2D in the paper by Huerta-Chagoya et. al. PRS created with the TagIt panel

always outperformed scores created with the HM3 panel across 5 major ancestry groups

(African/African American (AFR), Admixed American (AMR), East Asian (EAS), European

(EUR), and South Asian (SAS)). Given the HM3 and TagIt panels should work well in EAs, we

considered the improved performance of the TagIt panel over the standard HM3 panel in PRS-

CS could be due to better representation of HTN variants in the TagIt panel. However, given the

complexity and large number of SNPs in the PRS fully characterizing how differences in HTN

SNP representation drive performance was beyond the scope of our project. Unfortunately,

neither an expanded reference panel or functional annotations improved PRS performance

much in AAs, highlighting an important trend that PRS generally are less accurate in minority

populations. This is likely mostly driven by underrepresentation in the summary statistic data

and the benefits of a more diverse LD reference panel may not be fully observed until training

data becomes more representative.

Multi-ancestry HTN PRS have largely been trained on continuous-trait BP summary

statistics for SBP and DBP, rather than solely on summary statistics for dichotomous HTN, as

we did in this study.(28) In one recent study, Kurniansyah *et al*. trained a HTN PRS using

GWAS summary statistics from over 50,000 diverse samples and a P+ T approach using GWAS

data for SBP, DBP, and HTN, respectively.(29) A PRS was optimized for each trait and the trait-

specific PRSs were joined via an unweighted sum called "PRSsum" estimating the HTN-PRS. In

the validation phase of that study using over 30,000 participants from BioMe, the HTN-PRS had

an OR=1.32 per SD (95% CI: 1.2-1.4) for prevalent HTN in 8723 AAs and OR=1.47 per SD

(95% CI: 1.4-1.5) in 22463 EAs. In another study, that same PRS had OR=1.27 per SD (95%

CI 1.2-1.3) for prevalent HTN in a combined race sample of 98,590 from the All of Us network

(~20% AA). (28) Overall, there has been a lot of research focused on optimizing PRS for HTN in

diverse groups. In a multi-ancestry investigation of multiple BP PRS created by "clumping-and-

thresholding" (PRSice2), LDPred2 as well as PRS-CSx (a multi-ancestry modification of PRS-

CS), the PRS-CSx approach performed best across all race/ethnic backgrounds. They showed

that R^2 values for BP in AA participants were comparable to estimates reported in our study ~3-

3.5%.(28) Generally, the scores we developed in this study only improved marginally on

previous publications. The body of evidence shows multi-trait training data, multi-ancestry

representation in the summary data, modeling functional annotations, and improvements to the

reference LD panel all increase HTN PRS performance in EAs and AAs.(28, 29) As summary

statistic datasets grow and diversify, annotations improve, and computing resources expand

PRS, the gap in PRS performance between AAs and EAs for HTN should narrow.

This study developed PRS for HTN in well-characterized cohorts with EA and AA adults

with relevant genetic data from the REGARDS study. The scores developed were then tested

in a familial study of HTN (HyperGEN) with comparable phenotypic and genetic data resources.

We leveraged a novel LD reference panel developed by the PRISM Consortium, an NIH-funded

program that investigates the transportability of PRS. Limitations included that the multi-

ancestry summary statistics were predominantly derived from the UKB EA population, although

that dataset does have samples from multiple ancestry groups. In our testing cohort,

HyperGEN, some of the thresholded models had smaller participant counts (e.g. only 12

controls were in the top 5% for EAs) which likely inflated some of the OR estimates and made

confidence intervals around those estimates wide. Finally, given we only studied the EA and AA

populations, our work may not be generalizable to other ancestry groups.

In summary, we constructed multiple PRSs for HTN using Bayesian approaches

incorporating millions of SNPs for risk prediction. We showed that updating the reference panel

in PRS-CS and adding functional priors in LDPred-funct can improve HTN PRS performance.

While validation of the scores showed comparability and/or marginal improvement over

published data, the results still illustrate the difficulty of constructing PRS that can be clinically

informative. Expanding non-European genomic resources while leveraging the growing publicly

available annotation data, especially at the tissue and cell level is needed to continue to move

the field forward. Further, studies linking PRS to incident HTN will be necessary to evaluate if

scores for this common condition can aid in prevention and treatment.

276
277 <u>Methods</u>
278
279 *Study populations*
280
REGARDS is a national cohort established for the study of incident stroke and

associated risk factors. Between 2003 and 2007 over 30,239 AA and EA adults aged 45 years

or older were enrolled from all 48 contiguous US states and the District of Columbia.(30) At

baseline, participants completed a computer-assisted telephone interview followed by an in-

home visit that assessed blood pressure and other clinical measurements. REGARDS is

ongoing and since its inception, participants have been contacted at six-month intervals to

obtain information regarding incident stroke and secondary cardiovascular outcomes.

HyperGEN was a cross-sectional, population-based study designed to identify genetic risk

factors for HTN and target end-organ damage due to HTN.(31) The cohort, composed of self-

reported AA and EA sibships, was recruited from five field centers across the US (Forsyth

County, NC; Minneapolis, MN; Framingham, MA; Salt Lake City, UT; and Birmingham, AL).

Recruitment included sibling probands who were diagnosed with HTN before age 60, their

unmedicated adult offspring, and age-matched controls. In a later recruitment phase other

siblings of the original sibling pair as well as their children were included for a total sample size

of N=4584.

Informed consent was obtained from all subjects involved in the HyperGEN and REGARDS

studies. The REGARDS study was conducted according to the guidelines of the Declaration of

Helsinki and approved by the Institutional Review Board of the University of Alabama at

Birmingham (UAB IRB protocol number: IRB-020925004). The HyperGEN study was approved

by the same IRB (UAB IRB protocol number: IRB-160331004). The PRS research leveraging

these datasets was approved by UAB IRB protocol number: IRB-300006721.

303
304

Genotyping

A subset of 10,788 AA and EA REGARDS participants underwent genotyping using the

Illumina Infinium AMR/AFR (MEGA) BeadChip array. Quality control procedures have been

previously described, but briefly, internal duplicates and HapMap controls were excluded, as

well as samples whose genetic sex did not match the self-reported sex.[14] Variants were

excluded if they were located on sex chromosomes, had ambiguous strands, were not bi-allelic,

were in violation of Hardy Weinberg (p<1.00E-12 for AAs and p<1.00E-5 for EAs), and/or had a

missing rate >10%. Imputation in each ancestry separately was performed using the Trans-

Omics for Precision Medicine (TOPMed) release 2 (r2, Freeze 8) reference panel. [32] Imputed

variants were kept if r^2 >0.3 and genotypic probability >0.9. After QC a total of 6,146 AA HTN

cases and 2,457 AA controls contributed data to the analysis along with 896 and 637 EA HTN

cases and controls from REGARDS.

Genotyping of AA HyperGEN participants was performed through whole genome

sequencing (N=1,896).[33] In order to harmonize our imputation efforts with the array-based

panels of REGARDS, we subset common bi-allelic SNPs with MAF >1% overlapping with the

GWAS MEGA arrays used in REGARDS. This yielded a total of 2,204,415 SNPs that were used

as fence post variants for imputing the HyperGEN AA cohort using version r2 of the TOPMed

reference panel. Imputed variants were inspected for their imputation quality scores and

retained if r^2 >0.3 along with genotypic probability >0.9. HyperGEN EAs (N=1358) were

genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 (1.8 million variants).

Similarly to REGARDS, internal duplicates and HapMap controls were excluded, as well as

samples whose genetic sex did not match the self-reported sex. Variants were excluded if they

were located on sex chromosomes, had ambiguous strands, were not bi-allelic, were in violation

of Hardy Weinberg, and/or had a missing rate >10%. Imputation was performed using the

TOPMed r2 (Freeze 8) reference panel.[32] Imputed variants were retained if r^2 >0.3) and calls

had genotypic probability >0.9. After QC a total of 1315 and 581 AA HTN cases and controls

contributed data to the analysis, along with 697 and 573 EA HTN cases and controls from

HyperGEN.

335
336
337   *Phenotyping*
338
The measurement of blood pressure (BP) in the REGARDS study has been

described.(34) Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were defined

as the average of two measurements taken during the in-home visit by a trained technician

using a standardized protocol and regularly tested aneroid sphygmomanometer after the

participant was seated for five minutes. HTN was defined as SBP ≥140 and/or DBP ≥90 mmHg

and/or treatment with antihypertensive medication. The use of anti-hypertensive medication was

self-reported. In HyperGEN, BP measurements were made during the study visit, three times on

each arm. The participants rested for five minutes before measurement and 30 seconds

between measurements.(31) An average SBP and DBP were calculated based on the second

and third measurements in the second arm. Blood pressure measurements were obtained using

automated Dinamap devices (model 1846 SX/P, Critikon, Tampa, FL) to promote comparable

measurements among HyperGEN field centers. HTN was defined as average SBP ≥ 140 mmHg

or average DBP ≥ 90 mmHg, or using at least one class of antihypertensive medication.

352
353
354
PRS construction and optimization

The Bayesian methods applied require GWAS summary statistics, participant individual

level data for optimization and an external LD reference panel for PRS construction.(6, 11) We

leveraged Pan UK Biobank Multi-Ethnic GWAS summary statistics for HTN representing multi-

ancestry data from 420,473 European (EUR) individuals, 6,624 African (AFR) individuals, 8,849

South Asian (SAS) individuals, 2,707 East Asian (EAS) individuals, 998 Admixed American

(AMR), and 1,595 middle eastern ancestry individuals (MID).(35) For each PRS software

package, the REGARDS cohort served as the optimization cohort and HyperGEN as the

validation cohort.

We first applied PRS-CS using the HapMap3 (HM3) SNPs (default PRS-CS-HM3 LD

panel) [20] and a newly developed TagIt LD panel from the D-PRISM Consortium (developed

using the Tag(ging) It(erative) of SNPs in multiple populations (TagIt) program), designed to

enhance variants available for cross-ancestry prediction through leveraging variants and

samples from the 1000 Genomes project (PRS-CS-TagIt).(13, 27, 36, 37) The HM3 LD panel in

PRS-CS had 1,225,319 variants, whereas the expanded TagIt panel had 2,374,614 variants

with 729,110 overlapping between the two panels (6). To optimize the global scaling parameter

ϕ, we applied a grid search across four ϕ values (1.0, 1×10^{-02}, 1×10^{-04}, 1×10^{-06}) in the

optimization sample. In addition, we applied LDpred-funct, which is distinct from PRS-CS since

it leverages trait-specific functional priors for coding, conserved, regulatory, and LD-related

annotations.(11) LDpred-funct then uses both the functional priors and information on the LD

between variants from a 1000G phase 3 reference panel (including 1,217,312 variants) to

estimate the posterior mean causal effect sizes. To improve computational efficiency, we ran

the LDpred-funct program chromosome by chromosome. This allowed us to calculate weights at

the chromosomal level and then combine them for validation. As an input parameter, SNP-

heritability was calculated using LD score regression (LDSC). (38) See **Figure 1** for an outline

of our pipelines for each PRS development approach.

383
384
385

386
387 **Figure 1**. PRS Pipeline.
388
389

In total, we generated 20 PRSs for HTN in the REGARDS data (10 for each ancestry

group, where 4 (one for each ϕ) were output for PRS-CS-HM3, 4 (one for each ϕ) for PRS-CS-

TagIt, and 2 (raw and p-value based) for LD-Pred-funct). The predictive performance of each

PRS was assessed via a range of metrics. To measure the overall prediction accuracy, we

calculated the proportion of variation in the trait explained by the PRS on the liability scale (R^2

liability) after accounting for a basic set of covariates, including age, sex, and the top 10

ancestry principal components (PCs).(39, 40) Additionally, we calculated the area under the

curve (AUC) for a covariates-only model (age, sex, and top 10 PCs), a PRS-only model, and a

combined model (PRS plus covariates); and the odds ratio (OR) per standard deviation

(OR/SD) change in the PRS, as well as the thresholded ORs (top 2%, 5%, or 10% of the PRS

distribution relative to the remaining participants). Sensitivity, specificity, positive predictive

value (PPV; the proportion of identified high-risk individuals who are true HTN case subjects),

and negative predictive value (NPV; the proportion of unidentified individuals that are HTN

control subjects) are also reported. Since PPV and NPV depend on the prevalence of the

disease (we used 50% for both EAs and AAs), we report prevalence-adjusted PPV and NPV

similarly to a previous report.(41) We tested all the same metrics for the 10 scores in each

ancestry group in the HyperGEN cohort. All HyperGEN models were mixed models accounting

for familial relatedness. For all PRS-CS models the best ϕ value score for REGARDS as

determined by highest R^2 are presented in the main tables and is the focus of the validation in

HyperGEN.

410
411
412
413   **Supplemental Figure 1. AUC comparison for prediction of HTN.** A) AUC comparisons in AA
414   participants from REGARDS optimization cohort. B) AUC comparisons in AA participants from
415   HyperGEN validation cohort. C) AUC comparisons in EA participants from REGARD
416   optimization cohort. D) AUC comparisons in EA participants from HyperGEN validation cohort

Literature Cited

1.   Schunkert H, Di Angelantonio E, Inouye M, Patel RS, Ripatti S, Widen E, et al. Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease: A clinical consensus statement of the ESC Council on Cardiovascular Genomics, the ESC Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology. Eur Heart J. 2025;46(15):1372-83.

2.   Lennon NJ, Kottyan LC, Kachulis C, Abul-Husn NS, Arias J, Belbin G, et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat Med. 2024;30(2):480-7.

3.   Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12(1):44.

4.   Ni G, Zeng J, Revez JA, Wang Y, Zheng Z, Ge T, et al. A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. Biol Psychiatry. 2021;90(9):611-20.

5.   Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience. 2019;8(7).

6.   Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10(1):1776.

7.   Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, et al. Improved polygenic prediction by Bayesian multiple regression on summary statistics. Nat Commun. 2019;10(1):5086.

8.   Prive F, Arbel J, Vilhjalmsson BJ. LDpred2: better, faster, stronger. Bioinformatics. 2021;36(22-23):5424-31.

9.   Vilhjalmsson BJ, Yang J, Finucane HK, Gusev A, Lindstrom S, Ripke S, et al. Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am J Hum Genet. 2015;97(4):576-92.

10.   Jiang W, Chen L, Girgenti MJ, Zhao H. Tuning parameters for polygenic risk score methods using GWAS summary statistics from training data. Nat Commun. 2024;15(1):24.

11.   Marquez-Luna C, Gazal S, Loh PR, Kim SS, Furlotte N, Auton A, et al. Incorporating functional priors improves polygenic prediction accuracy in UK Biobank and 23andMe data sets. Nat Commun. 2021;12(1):6052.

12.   Zheng Z, Liu S, Sidorenko J, Wang Y, Lin T, Yengo L, et al. Leveraging functional genomic annotations and genome coverage to improve polygenic prediction of complex traits within and between ancestries. Nat Genet. 2024;56(5):767-77.

13.   Huerta-Chagoya A, Kim J, Mandla R, Lu Y, Suzuki K, Petty LE, et al. Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries. medRxiv. 2025.

14.   Armstrong ND, Srinivasasainagendra V, Patki A, Tanner RM, Hidalgo BA, Tiwari HK, et al. Genetic Contributors of Incident Stroke in 10,700 African Americans With Hypertension: A Meta-Analysis From the Genetics of Hypertension Associated Treatments and Reasons for Geographic and Racial Differences in Stroke Studies. Front Genet. 2021;12:781451.

15.   Jones AC, Patki A, Srinivasasainagendra V, Tiwari HK, Armstrong ND, Chaudhary NS, et al. Single-Ancestry versus Multi-Ancestry Polygenic Risk Scores for CKD in Black American Populations. J Am Soc Nephrol. 2024;35(11):1558-69.

16.   Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.

17.   Ndong Sima CAA, Step K, Swart Y, Schurz H, Uren C, Moller M. Methodologies underpinning polygenic risk scores estimation: a comprehensive overview. Hum Genet. 2024;143(11):1265-80.

18.   Norland K, Schaid DJ, Kullo IJ. Enhancing polygenic scores for cardiometabolic traits

through tissue- and cell-type-specific functional annotations. HGG Adv. 2025;6(3):100427.

19.   Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current
polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-91.

20.   Yengo L, Vedantam S, Marouli E, Sidorenko J, Bartell E, Sakaue S, et al. A saturated
map of common genetic variants associated with human height. Nature. 2022;610(7933):704-
12.

21.   Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal
variants by statistical fine-mapping. Nat Rev Genet. 2018;19(8):491-504.

22.   Patxot M, Banos DT, Kousathanas A, Orliac EJ, Ojavee SE, Moser G, et al. Probabilistic
inference of the genetic architecture underlying functional enrichment of complex traits. Nat
Commun. 2021;12(1):6972.

23.   Hu Y, Lu Q, Powles R, Yao X, Yang C, Fang F, et al. Leveraging functional annotations
in genetic risk prediction for human complex diseases. PLoS Comput Biol.
2017;13(6):e1005589.

24.   O'Connor LJ, Schoech AP, Hormozdiari F, Gazal S, Patterson N, Price AL. Extreme
Polygenicity of Complex Traits Is Explained by Negative Selection. Am J Hum Genet.
2019;105(3):456-76.

25.   Zeng J, de Vlaming R, Wu Y, Robinson MR, Lloyd-Jones LR, Yengo L, et al. Signatures
of negative selection in the genetic architecture of human complex traits. Nat Genet.
2018;50(5):746-53.

26.   Kachuri L, Chatterjee N, Hirbo J, Schaid DJ, Martin I, Kullo IJ, et al. Principles and
methods for transferring polygenic risk scores across global populations. Nat Rev Genet.
2024;25(1):8-25.

27.   Mercader JM, Ng MCY, Manning AK, Rich SS. Predicting diabetes risk in diverse
populations: what next? Lancet Diabetes Endocrinol. 2021;9(12):808-10.

28.   Kurniansyah N, Goodman MO, Khan AT, Wang J, Feofanova E, Bis JC, et al. Evaluating
the use of blood pressure polygenic risk scores across race/ethnic background groups. Nat
Commun. 2023;14(1):3202.

29.   Kurniansyah N, Goodman MO, Kelly TN, Elfassy T, Wiggins KL, Bis JC, et al. A multi-
ethnic polygenic risk score is associated with hypertension prevalence and progression
throughout adulthood. Nat Commun. 2022;13(1):3549.

30.   Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons
for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology.
2005;25(3):135-43.

31.   Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A, et al. NHLBI family
blood pressure program: methodology and recruitment in the HyperGEN network. Hypertension
genetic epidemiology network. Ann Epidemiol. 2000;10(6):389-400.

32.   Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation
genotype imputation service and methods. Nat Genet. 2016;48(10):1284-7.

33.   Kelly TN, Sun X, He KY, Brown MR, Taliun SAG, Hellwege JN, et al. Insights From a
Large-Scale Whole-Genome Sequencing Study of Systolic Blood Pressure, Diastolic Blood
Pressure, and Hypertension. Hypertension. 2022;79(8):1656-67.

34.   Howard G, Cushman M, Moy CS, Oparil S, Muntner P, Lackland DT, et al. Association
of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White
US Adults. JAMA. 2018;320(13):1338-48.

35.   Parcha V, Pampana A, Shetty NS, Irvin MR, Natarajan P, Lin HJ, et al. Association of a
Multiancestry Genome-Wide Blood Pressure Polygenic Risk Score With Adverse
Cardiovascular Events. Circ Genom Precis Med. 2022;15(6):e003946.

36.   Kullo IJ, Conomos MP, Nelson SC, Adebamowo SN, Choudhury A, Conti D, et al. The
PRIMED Consortium: Reducing disparities in polygenic risk assessment. Am J Hum Genet.
2024;111(12):2594-606.

37.   Wojcik GL, Fuchsberger C, Taliun D, Welch R, Martin AR, Shringarpure S, et al.
Imputation-Aware Tag SNP Selection To Improve Power for Large-Scale, Multi-ethnic
Association Studies. G3 (Bethesda). 2018;8(10):3255-67.
38.   Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working
Group of the Psychiatric Genomics C, et al. LD Score regression distinguishes confounding
from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291-5.
39.   Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease
from genome-wide association studies. Am J Hum Genet. 2011;88(3):294-305.
40.   Lee SH, Goddard ME, Wray NR, Visscher PM. A better coefficient of determination for
genetic profile analysis. Genet Epidemiol. 2012;36(3):214-24.
41.   Irvin MR, Ge T, Patki A, Srinivasasainagendra V, Armstrong ND, Davis B, et al.
Polygenic Risk for Type 2 Diabetes in African Americans. Diabetes. 2024;73(6):993-1001.

561
562
563
564

Funding/Support: This study was directly supported by National Institutes of Health (NIH) and
National Heart, Lung, and Blood Institute grants (R01HL136666 and R35HL155466, MRI). The
parent REGARDS study was supported by a cooperative agreement (U01NS041588) from the
National Institute of Neurological Disorders and Stroke, the NIH, and the US Department of
Health and Human Services. J.M.M. is supported by American Diabetes Association grant #11-
22-ICTSPM-16 and by NHGRI U01HG011723, by the National Institute Of Diabetes And
Digestive And Kidney Diseases of the National Institutes of Health under Award Number
R01DK137993 and U01 DK140757, AMP CMD award from RFP 6 from the Foundation for the
National Institutes of Health, and a Medical University of Bialystok (MUB) grant from the Ministry
of Science and Higher Education (Poland). This work is supported by the Novo Nordisk
Foundation (NNF21SA0072102). Z.W was supported by the National Heart, Lung, and Blood
Institute (K01HL171839)

577
578
579
580

21